论文部分内容阅读
目的:探讨EP方案同步放化疗治疗局限期小细胞肺癌疗效及安全性。方法:收治60例SCLC患者,分成A、B两组,A组开展同步放化疗治疗,B组开展交替放化疗,比较两组患者副作用与疗效。结果:A组副作用与B组相比,差异不明显(P>0.05);A组PFS长于B组,差异明显(P<0.05);两组OS比较,无明显意义(P>0.05)。结论:开展EP方案同步放化疗治疗SCLC虽然不能延长生存期,但可延长患者无进展生存期。
Objective: To investigate the efficacy and safety of EP regimen concurrent chemoradiotherapy in the treatment of limited-stage small cell lung cancer. Methods: Sixty patients with SCLC were divided into two groups A and B. Group A received concurrent chemoradiotherapy and chemotherapy. Group B received alternated chemoradiation and chemotherapy. The side effects and therapeutic effects were compared between the two groups. Results: The side effects of group A were not significantly different from those of group B (P> 0.05). The PFS of group A was longer than that of group B (P <0.05). There was no significant difference between the two groups (P> 0.05). Conclusion: The EP program of concurrent chemoradiotherapy for the treatment of SCLC although not extend the survival, but can extend the progression-free survival of patients.